Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Si...

FDA Recall #D-0122-2021 — Class II — December 8, 2020

Recall #D-0122-2021 Date: December 8, 2020 Classification: Class II Status: Terminated

Product Description

Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Single Dose Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, Jadcherla, 509301, India, Distributed by: Armas Pharmaceuticals, Inc. Manalapan, NJ 07726 NDC 72485-201-01.

Reason for Recall

CGMP Deviations

Recalling Firm

Shilpa Medicare Limited — Polepally, Jadcherla, N/A

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

35,931 vials

Distribution

Nationwide in the U.S.

Code Information

Lot #s: 7S10115A, Exp. 07/31/2021; 7S10143A, 7S10182B, Exp. 09/30/2021; 7S10255A, 7S10256A, 7S10263A, Exp. 11/30/2021; 7T10028A, 12/31/2021; 7T10040A, Exp. 01/31/2022.

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated